Compare Peloton Interactive Inc (PTON) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Peloton Interactive Inc vs TG Therapeutics Inc — how do they compare? Peloton Interactive Inc trades at $4.91 (market cap $2.13B), while TG Therapeutics Inc trades at $53.34 (market cap $8.11B). The key difference: TG Therapeutics Inc is far larger — about 3.8× Peloton Interactive Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Peloton Interactive Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Peloton Interactive Inc for 37 Days and TG Therapeutics Inc for 15 Days on average.
| PTON | TGTX | |
|---|---|---|
Market Cap | $2.13B | $8.11B |
Volume | 8,365,857 | 1,505,658 |
Sector | Consumer Cyclical | Health |
52-Week High | $7.86 | $59.06 |
52-Week Low | $3.71 | $26.94 |
Typical Hold Time | 37 Days | 15 Days |
Enterprise Value | $2.64B | $8.31B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Peloton Interactive (PTON) trades at $4.92, up 1.03% for the day, as the company shows signs of operational improvement with positive operating cash flow of $333M in 2025. The stock remains in a bearish technical trend with negative shareholder equity of -$413.7M, though recent product launches including the foldable Tread Flex aim to broaden market appeal. Revenue declined to $2.49B in 2025 with a net loss of $118.9M, but profitability metrics show gradual improvement from previous years.
While PTON faces significant challenges including high debt levels and declining membership, the company achieved its first profitable year in 2026 with $63M net income. Analyst consensus remains cautiously optimistic with a $8.00 price target representing 63% upside potential. Key risks include execution of the turnaround strategy and competitive pressure in the connected fitness market.
TG Therapeutics (TGTX) trades at $52.95, up 1.46% today, but faces bearish technical signals with recent earnings misses. The company shows strong profitability with 55.22% net margin and 100.28% ROE, while revenue growth continues with BRIUMVI capturing market share. Recent news includes shareholder litigation investigation and buyout speculation.
Despite earnings volatility, TGTX maintains strong fundamentals with analyst consensus at Buy (84.62%) and $80.50 price target. Key risks include ongoing legal scrutiny and execution on BRIUMVI growth, while institutional accumulation signals confidence in long-term prospects.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Peloton Interactive Inc
Peloton Interactive Inc operates an interactive fitness platform. It operates its business in two reportable segments: Connected Fitness Products and Subscription. Connected Fitness Product revenue consists of sales of bike and tread and related accessories, associated fees for delivery and installation, and extended warranty agreements. Subscription revenue consists of revenue generated from monthly Connected Fitness Subscription and Digital Subscription. The company generates the majority of the revenue from the sale of Connected Fitness Products.
Read more on PTON →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
